ID: ALA3962894

Max Phase: Preclinical

Molecular Formula: C14H11N3O3

Molecular Weight: 269.26

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC(=O)c1cc(-c2cn3cc(O)ccc3n2)ccc1O

Standard InChI:  InChI=1S/C14H11N3O3/c15-14(20)10-5-8(1-3-12(10)19)11-7-17-6-9(18)2-4-13(17)16-11/h1-7,18-19H,(H2,15,20)

Standard InChI Key:  JPSJWJIHWSYPQG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 269.26

Molecular Weight (Monoisotopic): 269.0800

AlogP: 1.51

#Rotatable Bonds: 2

Polar Surface Area: 100.85

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.73

CX Basic pKa: 5.81

CX LogP: 1.57

CX LogD: 1.49

Aromatic Rings: 3

Heavy Atoms: 20

QED Weighted: 0.66

Np Likeness Score: -1.13

References

1. Lawson M, Rodrigo J, Baratte B, Robert T, Delehouzé C, Lozach O, Ruchaud S, Bach S, Brion JD, Alami M, Hamze A..  (2016)  Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.,  123  [PMID:27474927] [10.1016/j.ejmech.2016.07.040]

Source

Source(1):

• Scientific Literature